Arcutis Biotherapeutics, Inc. (ARQT) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ARQT"
      ],
      "issuer_cik": "0001787306",
      "owner_cik": "0001801050",
      "accession_number": "0001628280-26-066331",
      "form_type": "4",
      "filing_date": "2026-10-19",
      "period_of_report": "2026-10-15",
      "issuer_name": "Arcutis Biotherapeutics, Inc.",
      "issuer_trading_symbol": "ARQT",
      "owner_name": "Welgus Howard G.",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-15",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 4728,
      "transaction_price_per_share": 26.93,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 35207,
      "transaction_value": 127325.04,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027."
        }
      ]
    },
    {
      "tickers": [
        "ARQT"
      ],
      "issuer_cik": "0001787306",
      "owner_cik": "0001798679",
      "accession_number": "0001628280-26-062732",
      "form_type": "4",
      "filing_date": "2026-09-18",
      "period_of_report": "2026-09-16",
      "issuer_name": "Arcutis Biotherapeutics, Inc.",
      "issuer_trading_symbol": "ARQT",
      "owner_name": "Matsuda Masaru",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-16",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 3674,
      "transaction_price_per_share": 25.0009,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 112508,
      "transaction_value": 91853.30660000001,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby\nundertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective\nprice within the range set forth in this footnote."
        }
      ],
      "remarks": "Reporting Person's title: EVP, Chief Legal Officer"
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.